Extended-Release Oxybutynin for the Treatment of Neurogenic Detrusor Overactivity
Status:
Terminated
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effects and tolerability (how well a participant
can stand a particular medicine or treatment) of flexible dose Oxybutynin Extended-Release
(OXY-ER, Lyrinel) including safety and quality of life assessment in participants with
neurogenic detrusor overactivity (NDO - the nerves mediating the detrusor muscle do not work
properly leading to frequent feeling of need to urinate during the day, night, or both).